Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

12.17
-0.4300-3.41%
Pre-market: 12.300.1300+1.07%06:46 EDT
Volume:661.25K
Turnover:8.14M
Market Cap:931.23M
PE:-8.46
High:12.78
Open:12.52
Low:12.13
Close:12.60
52wk High:14.00
52wk Low:4.35
Shares:76.52M
Float Shares:60.06M
Volume Ratio:0.85
T/O Rate:1.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4390
EPS(LYR):-0.7210
ROE:-81.84%
ROA:-28.64%
PB:7.38
PE(LYR):-16.88

Loading ...

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 04

Candel Therapeutics to Present Extended Phase 3 Data on Aglatimagene Besadenovec in Localized Prostate Cancer at ASTRO 2026

Reuters
·
Aug 03

Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston

GlobeNewswire
·
Jul 29

Candel Therapeutics Inc : Stifel Initiates Coverage with Buy Rating; Target Price $22

THOMSON REUTERS
·
Jul 13

Candel Therapeutics Initiated at Buy by Stifel

Dow Jones
·
Jul 13

Candel Therapeutics initiated with a Buy at Stifel

TIPRANKS
·
Jul 13

Candel Therapeutics Files Form 3 for Chief Commercial Officer Mark E. Sims

Reuters
·
Jul 09

Candel Therapeutics Grants New CCO Mark Sims Options for 285,000 Shares at $10.03 Each

Reuters
·
Jul 09

Candel Therapeutics Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 09

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 09

Candel Therapeutics Posts Corporate Presentation on Cancer Immunotherapy Pipeline Led by Can-2409 and Can-3110 Programs

Reuters
·
Jul 08

Candel Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Jul 07

Candel Therapeutics CTO Seshu Tyagarajan Sells 7,000 Common Shares for $70,151.20

Reuters
·
Jul 02

Candel Therapeutics Grants New Hire Options for 25,000 Shares at $10.3 Each

Reuters
·
Jul 02

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 02

Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-cancer Drug

Dow Jones
·
Jun 30

Candel Therapeutics Launches Phase 3 Aurora Trial of Can-2409 Combo in Advanced NSCLC

Reuters
·
Jun 30

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 Aurora Trial Evaluating Aglatimagene Besadenovec (can-2409) in Advanced Non-small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

THOMSON REUTERS
·
Jun 30

Candel Therapeutics Names Mark Sims Chief Commercial Officer

Reuters
·
Jun 25

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

THOMSON REUTERS
·
Jun 25